Last updated: November 2026
Atopic Dermatitis Breakthroughs: What’s New in Treatment
Atopic dermatitis, often called eczema, is one of the most common long-term skin conditions. It can’t be cured yet, but the past two years have brought several new FDA approvals, easier dosing and the first treatment guidelines written just for children. This guide explains each new atopic dermatitis treatment, who it’s for and what’s still in development.
For a full overview of every option, from moisturizers to pills, see our eczema treatment guide.
New Treatments at a Glance
| When | Advance | Type | Who it’s for |
|---|---|---|---|
| Jun 2026 | Ebglyss every-8-week maintenance dosing | Biologic injection | Moderate to severe, 12 and older (at least 88 lb) |
| Apr 2026 | First AAD guidelines for children with eczema | Treatment guidelines | Children and teens |
| Feb 2026 | Adquey (difamilast 1% ointment) approved | Steroid-free ointment | Mild to moderate, 2 and older |
| Oct 2025 | Zoryve cream 0.05% approved for young children | Steroid-free cream | Mild to moderate, ages 2 to 5 |
| Sep 2025 | Opzelura cream approved for children | Steroid-free cream | Mild to moderate, 2 and older |
| Dec 2024 | Nemluvio (nemolizumab) approved | Biologic injection | Moderate to severe, 12 and older |
| Dec 2024 | Vtama (tapinarof) cream approved for eczema | Steroid-free cream | 2 and older |
Breakthrough Treatments: Latest FDA Approvals, Biologics and Topicals
New Steroid-Free Creams and Ointments
Steroid creams still work well for flares, but many people want options they can use for longer or on sensitive skin. Four steroid-free choices now cover young children:
- Adquey (difamilast 1% ointment): approved in February 2026 for mild to moderate atopic dermatitis in people 2 and older. It’s a PDE4 inhibitor applied twice a day. In trials, more patients reached clear or almost clear skin at week 4 than with a non-medicated ointment. The most common side effect was a cold-like nose and throat infection.
- Zoryve (roflumilast) cream 0.05%: approved in October 2025 for children 2 to 5. It’s used once a day, anywhere on the body, for as long as needed. The stronger 0.15% cream has been approved for ages 6 and up since July 2024.
- Opzelura (ruxolitinib) cream: approved in September 2025 for children 2 and older, after first being approved for ages 12 and up in 2021. It’s a JAK inhibitor cream for short-term, on-and-off use when other prescription creams haven’t worked. It carries a boxed warning shared by all JAK inhibitors.
- Vtama (tapinarof) cream: approved in December 2024 for atopic dermatitis in people 2 and older. Up to 46% of patients were clear or almost clear at week 8, and some noticed less itch within 24 hours. Its label has no limits on how long or how much of the body it can be used on.
Biologic Injections: More Options, Fewer Shots
Biologics are injected just under the skin, usually at home. They block specific signals that drive eczema inflammation and itch.
- Nemluvio (nemolizumab): approved in December 2024 for moderate to severe atopic dermatitis in people 12 and older, used along with prescription creams. It’s the first biologic that targets IL-31, a key itch signal. In trials, itch improved as early as week 1. Once eczema is under control, it’s injected every 4 weeks.
- Ebglyss (lebrikizumab): in June 2026 the FDA approved a maintenance dose once every 8 weeks, for people 12 and older who weigh at least 88 lb. That means as few as six maintenance shots a year.
- Dupixent (dupilumab): the first of these medicines, approved in 2017, is now approved for children as young as 6 months.
Biologics for eczema are not given by IV infusion. Each one is an injection under the skin.
JAK Inhibitor Pills
Rinvoq (upadacitinib) and Cibinqo (abrocitinib) are once-a-day pills for moderate to severe atopic dermatitis in people 12 and older when other treatments haven’t worked well or aren’t recommended. Some patients feel less itch within days. They carry an FDA boxed warning, so dermatologists check your health history first. Read more in our guide to JAK inhibitors for atopic dermatitis.
First Treatment Guidelines for Children With Eczema
In April 2026 the American Academy of Dermatology (AAD) published its first guidelines for treating atopic dermatitis in children and teens. They strongly recommend:
- Moisturizers, topical steroids and topical calcineurin inhibitors
- Steroid-free creams: crisaborole, roflumilast (Zoryve), ruxolitinib (Opzelura) and tapinarof (Vtama)
- Biologics: dupilumab, tralokinumab and lebrikizumab
- JAK inhibitor pills: upadacitinib, abrocitinib and baricitinib
They strongly recommend against steroid pills or shots for children’s eczema. Light therapy, bleach baths and older immune-suppressing pills are conditional options. If your child has eczema, a pediatric dermatology visit can help you choose.
Looking Ahead: Treatments in Development
Research continues, though not every promising drug makes it to approval:
- Zoryve for babies: the FDA is reviewing Zoryve cream 0.05% for infants 3 months to under 2 years, with a decision expected by February 23, 2027.
- KT-621, a once-daily pill: this experimental drug blocks STAT6, a protein that carries the same IL-4 and IL-13 signals that Dupixent blocks. A trial of about 200 patients finished enrolling, with results expected by the end of 2026 and larger trials planned for mid-2027.
- Amlitelimab, stopped: in July 2026 Sanofi ended development of this injection for eczema. It worked, but the company said it wouldn’t meaningfully improve on current treatments.
New options take years of testing. Some patients may be able to join a study through our clinical trials program.
What These Advances Mean for You
More options mean more chances to find a treatment that fits your skin, age and lifestyle. Daily moisturizing and avoiding triggers are still the base for everyone. See our guide to moisturizers and skin care for eczema.
A dermatologist will consider:
- How severe your eczema is: mild eczema often clears with creams; moderate to severe may need a biologic, pill or light therapy.
- Your age: approvals differ, and several now include young children.
- Where it is: the face, eyelids and skin folds need gentle options.
- Your health history: this affects which pills and injections are safe.
- Your preferences: cream, injection or pill, and how often.
Conclusion
Atopic dermatitis treatment has changed quickly. In the past two years there have been new steroid-free creams for young children, a new type of biologic for itch, fewer injections with Ebglyss, and the first children’s guidelines. More options are still being studied.
If you live in the Raleigh, Durham or Chapel Hill area, you can see Dr. Stefan Weiss, a board-certified dermatologist and member of the National Eczema Association. Schedule a consultation to talk about which new treatment may be right for you.
Frequently asked questions
The newest FDA approval is Adquey (difamilast 1% ointment), approved in February 2026 for mild to moderate atopic dermatitis in people 2 and older. In June 2026 Ebglyss was also approved for maintenance shots every 8 weeks.
Yes. Zoryve cream 0.05% (ages 2 to 5), Opzelura cream (2 and older), Vtama cream (2 and older) and Adquey ointment (2 and older) are all steroid-free options. Dupixent injections are approved for children as young as 6 months.
Biologic injections such as Nemluvio, Ebglyss, Adbry and Dupixent, and JAK inhibitor pills such as Rinvoq and Cibinqo, are used for moderate to severe eczema. Ebglyss can now be given as few as six times a year once eczema is under control.
Rinvoq and Cibinqo are once-daily pills already approved for moderate to severe eczema in people 12 and older. A new experimental pill, KT-621, is in a mid-stage trial with results expected by the end of 2026.
See a dermatologist when eczema keeps coming back, disturbs sleep or daily life, or doesn't improve with daily moisturizing and over-the-counter care. Prescription creams, injections, pills and light therapy are all options.
Not yet. There is no cure, but treatment can control it, and for many children eczema goes away by their teenage years. Newer treatments give more people a way to keep their skin clear for longer.
About Dr. Weiss
Stefan C. Weiss, MD, FAAD, is a board-certified dermatologist, the medical director of Trillium Clinic and an adjunct professor of dermatology at Brown University. He trained at Duke University School of Medicine and Stanford University Medical Center, has authored more than 100 peer-reviewed abstracts, posters and manuscripts, and has over two decades of experience in medical and cosmetic dermatology.
References
- Acrotech Biopharma. FDA approval of Adquey (difamilast 1%) ointment. February 2026.
- Eli Lilly. FDA approves Ebglyss for one maintenance dose every eight weeks. June 2026.
- Arcutis Biotherapeutics. FDA approves Zoryve cream 0.05% for atopic dermatitis in children ages 2 to 5. October 2025.
- Arcutis Biotherapeutics. FDA accepts application for Zoryve cream 0.05% in infants down to 3 months. July 2026.
- Incyte. FDA approval of Opzelura cream in children ages 2 to 11 with atopic dermatitis. September 2025.
- Galderma. FDA approval for Nemluvio (nemolizumab) in moderate-to-severe atopic dermatitis. December 2024.
- Organon. FDA approves Vtama (tapinarof) cream 1% for atopic dermatitis. December 2024.
- American Academy of Dermatology. Pediatric atopic dermatitis guideline. 2026.
- American Academy of Dermatology. Atopic dermatitis: diagnosis and treatment.
- American Academy of Dermatology. Can eczema be cured?
- Kymera Therapeutics. KT-621 presentations and BROADEN2 update. September 2026.
- Sanofi. Decision not to submit amlitelimab in atopic dermatitis. July 2026.
This article is for general education and isn’t a substitute for personal medical advice. A board-certified dermatologist can tell you which treatment is right for you.
